Home Tools
Log in
Cart

JAK

The JAK-STAT signalling pathway is a chain of interactions between proteins in a cell, and is involved in processes such as immunity, cell division, cell death and tumour formation. There are 4 JAK proteins: JAK1, JAK2, JAK3 and TYK2. JAKs contains a FERM domain (approximately 400 residues), an SH2-related domain (approximately 100 residues), a kinase domain (approximately 250 residues) and a pseudokinase domain (approximately 300 residues). The kinase domain is vital for JAK activity, since it allows JAKs to phosphorylate (add phosphate groups to) proteins.
Signaling Pathways | Target | TargetMol
Cat. No. Product name CAS No. Purity Chemical Structure
T22319 DTP3 1809784-29-9 99.57%
DTP3
DTP3 is a selective MKK7/GADD45β inhibitor, which inhibits cancer-selective NF-κB survival pathway.
T6933 Peficitinib 944118-01-8 98.67%
Peficitinib
Peficitinib (ASP015K) (ASP015K, JNJ-54781532) is an orally bioavailable JAK inhibitor. Phase 3.
T2460 JAK 3 inhibitor IV 58753-54-1 98%
JAK 3 inhibitor IV
JAK 3 inhibitor IV (ZM 39923 hydrochloride) is a JAK1/3 inhibitor with pIC50 of 4.4/7.1, almost no activity to JAK2 and modestly potent to EGFR; also found to be...
T2653 SB1317 1204918-72-8 100%
SB1317
SB1317 (TG02) is a potent inhibitor of cyclin dependant kinases (CDKs), Janus kinase 2 (JAK2), and Fms-like tyrosine kinase-3 (FLT3).
T11710L JAK-IN-5 hydrochloride 2751323-21-2
JAK-IN-5 hydrochloride
JAK-IN-5 hydrochloride is a JAK inhibitor [1].
T11709 JAK3 covalent inhibitor-1 2300106-50-5 98%
JAK3 covalent inhibitor-1
JAK3 covalent inhibitor-1 is a potent and selective janus kinase 3 (JAK3) covalent inhibitor with an IC50 of 11 nM and shows 246-fold selectivity vs other JAKs.
T11713 JBJ-02-112-05 2748162-29-8 98%
JBJ-02-112-05
JBJ-02-112-05 is a potent, mutant-selective, allosteric and orally active inhibitor of EGFR with an IC 50 of 15 nM for EGFR L858R/T790M [1].
T16995 TAS05567 1429038-15-2 98%
TAS05567
TAS05567 is a potent, highly selective, and ATP-competitive Syk inhibitor (IC50: 0.37 nM). TAS05567 only shows >70% inhibition of Syk and 4 other kinases (FLT3, ...
T77943 SJ1008030 TFA 98%
SJ1008030 TFA
SJ1008030 (compound 8) TFA is a selective JAK2-degrading PROTAC that inhibits the growth of MHH-CALL-4 leukemia cells with an IC50 of 5.4 nM, indicating its pote...
T78175 JAK-IN-25 2127110-22-7 98%
JAK-IN-25
JAK-IN-25 (compound 19), a potent JAK inhibitor, exhibits IC50 values of 6 nM for TYK2, 21 nM for JAK1, 8 nM for JAK2, and 1051 nM for JAK3. It also demonstrates...
T78189 JAK-IN-26 2417134-93-9 98%
JAK-IN-26
JAK-IN-26 (compound 2) is an orally active inhibitor of the Janus kinase (JAK) enzyme with favorable pharmacokinetic properties, exhibiting potency in suppressin...
T78207 Lepzacitinib 2321488-47-3 98%
Lepzacitinib
Lepzacitinib, a Janus kinase inhibitor, specifically targets JAK 1/3. It demonstrates an anti-inflammatory effect and efficacy in inhibiting atopic dermatitis as...
T78708 JAK/HDAC-IN-2 98%
JAK/HDAC-IN-2
JAK/HDAC-IN-2, a potent 2-amino-4-phenylaminopyrimidine dual-target inhibitor, effectively suppresses JAK1/2 and HDAC3/6 at nanomolar concentrations. This compou...
T79078 JAK1-IN-10 2416858-88-1 98%
JAK1-IN-10
JAK1-IN-10 (compound 9), a cyano-substituted cyclic hydrazine derivative, functions as a potent and selective inhibitor of JAK1 [1].
T79079 JAK1-IN-11 2427608-43-1 98%
JAK1-IN-11
JAK1-IN-11 (compound 11) serves as a potent inhibitor of Janus kinases, exhibiting nanomolar inhibitory concentrations with IC50 values of 0.02 nM (JAK1) and 0.4...
T79110 JAK-IN-27 2673176-36-6 98%
JAK-IN-27
JAK-IN-27, also known as compound 1, is an orally active, potent inhibitor of the JAKS family kinases, displaying inhibitory concentrations (IC50s) of 3.0 nM for...
T79116 JAK-IN-28 2445500-22-9 98%
JAK-IN-28
JAK-IN-28 (Compound 111) is a Janus kinase (JAK) inhibitor potentially applicable in the research of cancer and inflammatory diseases [1].
T79222 JAK-IN-29 98%
JAK-IN-29
JAK-IN-29 (Compound 3) is a potent inhibitor of Janus kinases (JAK) [1].
T79235 JAK-IN-30 2891469-99-9 98%
JAK-IN-30
JAK-IN-30 (compound 31) is a water-soluble inhibitor of Janus kinases (JAKs), demonstrating inhibitory potency with half-maximal inhibitory concentration (IC50) ...
T79581 JAK2-IN-9 2568842-26-0 98%
JAK2-IN-9
Compound A8, known as JAK2-IN-9, is a selective JAK2 inhibitor with an IC50 of 5 nM. It effectively inhibits the phosphorylation of JAK2, STAT3, and STAT5, posse...
DTP3
T22319
DTP3 is a selective MKK7/GADD45β inhibitor, which inhibits cancer-selective NF-κB survival pathway.
Peficitinib
T6933
Peficitinib (ASP015K) (ASP015K, JNJ-54781532) is an orally bioavailable JAK inhibitor. Phase 3.
JAK 3 inhibitor IV
T2460
JAK 3 inhibitor IV (ZM 39923 hydrochloride) is a JAK1/3 inhibitor with pIC50 of 4.4/7.1, almost no activity to JAK2 and modestly potent to EGFR; also found to be...
SB1317
T2653
SB1317 (TG02) is a potent inhibitor of cyclin dependant kinases (CDKs), Janus kinase 2 (JAK2), and Fms-like tyrosine kinase-3 (FLT3).
JAK-IN-5 hydrochloride
T11710L
JAK-IN-5 hydrochloride is a JAK inhibitor [1].
JAK3 covalent inhibitor-1
T11709
JAK3 covalent inhibitor-1 is a potent and selective janus kinase 3 (JAK3) covalent inhibitor with an IC50 of 11 nM and shows 246-fold selectivity vs other JAKs.
JBJ-02-112-05
T11713
JBJ-02-112-05 is a potent, mutant-selective, allosteric and orally active inhibitor of EGFR with an IC 50 of 15 nM for EGFR L858R/T790M [1].
TAS05567
T16995
TAS05567 is a potent, highly selective, and ATP-competitive Syk inhibitor (IC50: 0.37 nM). TAS05567 only shows >70% inhibition of Syk and 4 other kinases (FLT3, ...
SJ1008030 TFA
T77943
SJ1008030 (compound 8) TFA is a selective JAK2-degrading PROTAC that inhibits the growth of MHH-CALL-4 leukemia cells with an IC50 of 5.4 nM, indicating its pote...
JAK-IN-25
T78175
JAK-IN-25 (compound 19), a potent JAK inhibitor, exhibits IC50 values of 6 nM for TYK2, 21 nM for JAK1, 8 nM for JAK2, and 1051 nM for JAK3. It also demonstrates...
JAK-IN-26
T78189
JAK-IN-26 (compound 2) is an orally active inhibitor of the Janus kinase (JAK) enzyme with favorable pharmacokinetic properties, exhibiting potency in suppressin...
Lepzacitinib
T78207
Lepzacitinib, a Janus kinase inhibitor, specifically targets JAK 1/3. It demonstrates an anti-inflammatory effect and efficacy in inhibiting atopic dermatitis as...
JAK/HDAC-IN-2
T78708
JAK/HDAC-IN-2, a potent 2-amino-4-phenylaminopyrimidine dual-target inhibitor, effectively suppresses JAK1/2 and HDAC3/6 at nanomolar concentrations. This compou...
JAK1-IN-10
T79078
JAK1-IN-10 (compound 9), a cyano-substituted cyclic hydrazine derivative, functions as a potent and selective inhibitor of JAK1 [1].
JAK1-IN-11
T79079
JAK1-IN-11 (compound 11) serves as a potent inhibitor of Janus kinases, exhibiting nanomolar inhibitory concentrations with IC50 values of 0.02 nM (JAK1) and 0.4...
JAK-IN-27
T79110
JAK-IN-27, also known as compound 1, is an orally active, potent inhibitor of the JAKS family kinases, displaying inhibitory concentrations (IC50s) of 3.0 nM for...
JAK-IN-28
T79116
JAK-IN-28 (Compound 111) is a Janus kinase (JAK) inhibitor potentially applicable in the research of cancer and inflammatory diseases [1].
JAK-IN-29
T79222
JAK-IN-29 (Compound 3) is a potent inhibitor of Janus kinases (JAK) [1].
JAK-IN-30
T79235
JAK-IN-30 (compound 31) is a water-soluble inhibitor of Janus kinases (JAKs), demonstrating inhibitory potency with half-maximal inhibitory concentration (IC50) ...
JAK2-IN-9
T79581
Compound A8, known as JAK2-IN-9, is a selective JAK2 inhibitor with an IC50 of 5 nM. It effectively inhibits the phosphorylation of JAK2, STAT3, and STAT5, posse...
1 2 3 4 5 6 7 8 9
TargetMol